# Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/everolimus-for-angiomyolipoma-associated-with-tuberous-sclerosis-complex-or/

## Facts

| Field | Value |
| --- | --- |
| Author Names | John J. Bissler,J.C. Kingswood,Elżbieta Radzikowska,Bernard A. Zonnenberg,Michael Frost,Е. Д. Белоусова,Matthias Sauter,Norio Nonomura,Susanne Brakemeier,Petrus J. de Vries,Vicky Whittemore,David Chen,Tarek Sahmoud,Gaurav Shah,Jeremie Lincy,David Lebwohl,Klemens Budde |
| Citations | 888 |
| DOI | 10.1016/s0140-6736(12)61767-x |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2134749898 |
| PMID | 23312829 |
| Type | article |
| Year | 2013 |

## Paper authors

- [Klemens Budde](https://scholariq.org/researchers/klemens-budde/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Tuberous Sclerosis Complex Research](https://scholariq.org/topics/tuberous-sclerosis-complex-research/)

## Paper topics

- [Tuberous Sclerosis Complex Research](https://scholariq.org/topics/tuberous-sclerosis-complex-research/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Vascular Tumors and Angiosarcomas](https://scholariq.org/topics/vascular-tumors-and-angiosarcomas/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.